The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. METHODS: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, at a dose of 60 mg, administered subcutaneously every 6 months. The coprimary end points were the cumulative incidences of new vertebral fractures at 12 months and 24 months. Secondary end points included clinical (a composite of nonvertebral and symptomatic vertebral) and nonvertebral fractures. RESULTS: At 12 months, new vertebral fractures had occurred in 16 of 3321 patients (0.5%) in the romosozumab group, as compared with 59 of 3322 (1.8%) in the placebo group (representing a 73% lower risk with romosozumab; P<0.001). Clinical fractures had occurred in 58 of 3589 patients (1.6%) in the romosozumab group, as compared with 90 of 3591 (2.5%) in the placebo group (a 36% lower risk with romosozumab; P=0.008). Nonvertebral fractures had occurred in 56 of 3589 patients (1.6%) in the romosozumab group and in 75 of 3591 (2.1%) in the placebo group (P=0.10). At 24 months, the rates of vertebral fractures were significantly lower in the romosozumab group than in the placebo group after each group made the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001). Adverse events, including instances of hyperostosis, cardiovascular events, osteoarthritis, and cancer, appeared to be balanced between the groups. One atypical femoral fracture and two cases of osteonecrosis of the jaw were observed in the romosozumab group. CONCLUSIONS: In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It achieves this by upregulating the Wnt pathway while also acting as an enhancer of RANKL synthesis, thereby downregulating this latter pathway [83,84,85].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it uniquely exhibits the ability to stimulate bone formation while simultaneously reducing bone resorption.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Romosozumab is a newly approved monoclonal antibody targeting sclerostin.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A systematic review of hip fracture incidence and probability of fracture worldwide
Kanis, J. A., Odén, A., McCloskey, E. V., Johansson, H., Wahl, D. A., Cooper, C. C., & on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) · Osteoporosis International · doi:10.1007/s00198-012-1964-3 · Cited by 1,382
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Estimating Hip Fracture Morbidity, Mortality and Costs
Braithwaite, R. S., Col, N. F., & Wong, J. B. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51110.x · Cited by 915
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,001
Cytokine-mediated immunomodulation of osteoclastogenesis
Zhou, P., Zheng, T., & Zhao, B. (2022) · Bone · doi:10.1016/j.bone.2022.116540 · Cited by 148
Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures
Starr, J., Tay, D., & Shane, E. J. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0464-6 · Cited by 132
Kawahara, M., Kuroshima, S., & Sawase, T. (2021) · International Journal of Implant Dentistry · doi:10.1186/s40729-021-00323-0 · Cited by 132
Current use of bone turnover markers in the management of osteoporosis
Brown, J. P., Don-Wauchope, A., Douville, P., Albert, C., & Vasikaran, S. D. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.09.002 · Cited by 139
Bhattoa, H. P., Vasikaran, S. D., Trifonidi, I., Kapoula, G., Lombardi, G., Jørgensen, N. R., Pikner, R., Miura, M., Chapurlat, R. D., Hiligsmann, M., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07422-3 · Cited by 148
Management of Osteoporosis in CKD
Khairallah, P., & Nickolas, T. L. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11031017 · Cited by 127
Medication-related osteonecrosis of the jaw: A literature review
Kuroshima, S., Sasaki, M., & Sawase, T. (2019) · Journal of Oral Biosciences · doi:10.1016/j.job.2019.03.005 · Cited by 142
Kendler, D. L., Bone, H. G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S. V., Dinavahi, R. V., Libanati, C. R., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05146-9 · Cited by 129
Self-citationBone Mineral Density: Clinical Relevance and Quantitative Assessment
Haseltine, K., Chukir, T., Smith, P. J., Jacob, J. T., Bilezikian, J. P., & Farooki, A. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.256180 · Cited by 138
Antiresorptive and anabolic agents in the prevention and reversal of bone fragility
Seeman, E., & Martin, T. J. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0172-3 · Cited by 127
Yang, W., Li, H., Wu, Y., Mi, R., Liu, W. Z., Shen, X., Lu, Y., Jiang, Y., Ma, M. J., & Shen, H. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.022 · Cited by 124
Anastasilakis, A. D., Pοlyzos, S. A., & Makras, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0056 · Cited by 126
Management of Osteogenesis Imperfecta
Ralston, S. H., & Gaston, M. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00924 · Cited by 124
WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders
Huybrechts, Y., Mortier, G. R., Boudin, E., & Hul, W. V. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00165 · Cited by 123
Subarajan, P., Arceo-Mendoza, R. M., & Camacho, P. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.08.008 · Cited by 136
Osteogenesis imperfecta and therapeutics
Morello, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.010 · Cited by 125
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 121
Rheumatoid Arthritis in the View of Osteoimmunology
Auréal, M., Machuca‐Gayet, I., & Coury, F. (2020) · Biomolecules · doi:10.3390/biom11010048 · Cited by 126
Bovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6570 · Cited by 119
Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease
Hutcheson, J. D., & Goettsch, C. (2023) · Circulation Research · doi:10.1161/circresaha.123.321760 · Cited by 125
Lv, F., Cai, X., Yang, W., Gao, L., Chen, L., Wu, J., & Ji, L. (2019) · Bone · doi:10.1016/j.bone.2019.115121 · Cited by 121
Self-citationRomosozumab and antiresorptive treatment: the importance of treatment sequence
Cosman, F., Kendler, D. L., Langdahl, B. L., Leder, B. Z., Lewiecki, E. M., Miyauchi, A., Rojeski, M., McDermott, M., Oates, M. K., Milmont, C. E., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06174-0 · Cited by 118
Self-citationChen, C., Rao, S., Tan, Y., Luo, M., Hu, X., Yin, H., Huang, J., Hu, Y., Luo, Z., Liu, Z., et al. (2019) · Bone Research · doi:10.1038/s41413-019-0056-9 · Cited by 116
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
Estell, E. G., & Rosen, C. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00426-5 · Cited by 115
Assessment and treatment of osteoporosis and fractures in type 2 diabetes
Sheu, A., Greenfield, J. R., & White, C. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.02.006 · Cited by 119
Sclerostin inhibition alleviates breast cancer–induced bone metastases and muscle weakness
Hesse, E., Schröder, S., Brandt, D., Pamperin, J., Saito, H., & Taipaleenmäki, H. (2019) · JCI Insight · doi:10.1172/jci.insight.125543 · Cited by 113
Yu, M. S., Qin, K. H., Fan, J., Zhao, G., Zhao, P., Zeng, W., Chen, C., Wang, A., Wang, Y., Zhong, J., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.04.042 · Cited by 125
Targeting WNT signaling in the treatment of osteoporosis
Baron, R., & Gori, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.011 · Cited by 101
van de Laarschot, D. M., McKenna, M. J., Abrahamsen, B., Langdahl, B. L., Cohen-Solal, M. E., Guañabens, N., Eastell, R., Ralston, S. H., & Zillikens, M. C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz295 · Cited by 114
Management of patients at very high risk of osteoporotic fractures through sequential treatments
Curtis, E. M., Reginster, J., Al‐Daghri, N. M., Biver, E., Brandi, M. L., Cavalier, E., Hadji, P., Halbout, P., Harvey, N. C., Hiligsmann, M., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02100-4 · Cited by 118
A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment
Wu, B., Fu, Z., Wang, X., Zhou, P., Yang, Q., Jiang, Y., & Zhu, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1052592 · Cited by 114
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D., Avgerinou, C., Bowden, J., Cooper, C. C., Douglas, L., Edwards, J., Gittoes, N. J. L., Harvey, N. C., Kanis, J. A., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01588-3 · Cited by 136
Wnt signaling in cardiovascular disease: opportunities and challenges
Gay, A., & Towler, D. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000445 · Cited by 117
Mineral bone disorders in chronic kidney disease
Hou, Y., Lu, C., & Lu, K. (2018) · Nephrology · doi:10.1111/nep.13457 · Cited by 113
Ferrari, S., Libanati, C. R., Lin, C. J. F., Brown, J. P., Cosman, F., Czerwinski, E. J., de Gregorio, L. H., Malouf, J., Reginster, J.-Y., Wang, A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3722 · Cited by 116
Self-citationPhysiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R
Martin, T. J., Sims, N. A., & Seeman, E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab005 · Cited by 118
Ishibashi, H., Crittenden, D. B., Miyauchi, A., Libanati, C. R., Maddox, J., Fan, M., Chen, L., & Grauer, A. (2017) · Bone · doi:10.1016/j.bone.2017.07.005 · Cited by 110
Self-citationProspect of mesenchymal stem cells in therapy of osteoporosis: A review
Maleki, L. A., Dolati, S., Zandi, R., Fotouhi, A., Ahmadi, M., Aghebati, A., Nouri, M., Shakouri, S. K., & Yousefi, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27833 · Cited by 110
Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
Wang, J. S., Mazur, C. M., & Wein, M. N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.584147 · Cited by 113
Regulation of bone homeostasis: signaling pathways and therapeutic targets
Wu, Z., Li, W., Jiang, K., Lin, Z., Qian, C., Wu, M., Xia, Y., Li, N., Zhang, H., Xiao, H.-X., et al. (2024) · MedComm · doi:10.1002/mco2.657 · Cited by 129
Osteoporosis Management in the Era of COVID-19
Yu, E. W.-Y., Tsourdi, E. A., Clarke, B. L., Bauer, D. C., & Drake, M. T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4049 · Cited by 109
New Insights into Monogenic Causes of Osteoporosis
Mäkitie, R. E., Costantini, A., Kämpe, A., Alm, J. J., & Mäkitie, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00070 · Cited by 108
Sfeir, J. G., Drake, M. T., Khosla, S., & Farr, J. N. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.03.011 · Cited by 112
Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases
Coury, F., Peyruchaud, O., & Machuca‐Gayet, I. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00679 · Cited by 110
Current and Future Concepts for the Treatment of Impaired Fracture Healing
Schlickewei, C., Kleinertz, H., Thiesen, D. M., Mader, K., Priemel, M., Frosch, K., & Keller, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225805 · Cited by 107
Novel actions of sclerostin on bone
Holdsworth, G., Roberts, S. J., & Ke, H. Z. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0176 · Cited by 109
Bone health and menopause: Osteoporosis prevention and treatment
de Villiers, T. J. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101782 · Cited by 110
Kanis, J. А., Cooper, C. C., Rizzoli, R., Abrahamsen, B., Al‐Daghri, N. M., Brandi, M. L., Cannata-Andía, J. B., Cortet, B., Dimai, H. P., Ferrari, S., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4161-6 · Cited by 105
Self-citationOminsky, M. S., Boyd, S. K., Varela, A., Jolette, J., Felx, M., Doyle, N. E., Mellal, N., Smith, S. Y., Locher, K., Buntich, S., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3036 · Cited by 104
Osteoanabolic Agents for Osteoporosis
Haas, A. V., & LeBoff, M. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00118 · Cited by 103
Romero-Díaz, C., Duarte‐Montero, D., Gutiérrez-Romero, S. A., & Mendivil, C. O. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00964-1 · Cited by 107
Keaveny, T. M., Crittenden, D. B., Bolognese, M. A., Genant, H. K., Engelke, K., Oliveri, B., Brown, J. P., Langdahl, B. L., Yan, C., Grauer, A., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3176 · Cited by 104
Self-citationRochette, L., Méloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.015 · Cited by 108
Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab—a review
King, R., Tanna, N., & Patel, V. (2018) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2018.11.012 · Cited by 104
On the utilization of polygenic risk scores for therapeutic targeting
Gibson, G. C. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008060 · Cited by 102
Osteoporosis therapies and their mechanisms of action (Review)
Kim, B., Cho, Y., & Lim, W. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10815 · Cited by 106
Miller, P. D., Adachi, J. D., Albergaria, B., Cheung, A. M., Chines, A. A., Gielen, E., Langdahl, B. L., Miyauchi, A., Oates, M. K., Reid, I. R., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4563 · Cited by 106
Self-citationThe prevention of osteoporosis and sarcopenia in older adults
Coll, P. P., Phu, S., Hajjar, S. H., Kirk, B., Duque, G., & Taxel, P. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17043 · Cited by 101
Romosozumab for the treatment of osteoporosis
Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280455 · Cited by 101
Self-citationPimolbutr, K., Porter, S. R., & Fedele, S. (2018) · BioMed Research International · doi:10.1155/2018/8071579 · Cited by 101
Postmenopausal osteoporosis: Assessment and management
Rizzoli, R. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.09.005 · Cited by 107
Profile of romosozumab and its potential in the management of osteoporosis
Lim, S. Y., & Bolster, M. B. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s127568 · Cited by 106
Denosumab versus romosozumab for postmenopausal osteoporosis treatment
Kobayakawa, T., Miyazaki, A., Saito, M., Suzuki, T., Takahashi, J. A., & Nakamura, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-91248-6 · Cited by 100
Fredericson, M., Kussman, A. L., Misra, M., Barrack, M. T., Souza, M. J. D., Kraus, E., Koltun, K. J., Williams, N. I., Joy, E. A., & Nattiv, A. (2021) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000948 · Cited by 109
The critical interplay between bone resorbing and bone forming cells
Lerner, U. H., Kindstedt, E., & Lundberg, P. (2019) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13051 · Cited by 100
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates
Cummings, S. R., Lui, L., Eastell, R., & Allen, I. E. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2779 · Cited by 99
Sclerostin: from bench to bedside
Tanaka, S., & Matsumoto, T. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01176-0 · Cited by 97
Crosstalk between the gut microbiota and postmenopausal osteoporosis: Mechanisms and applications
Xu, Q., Li, D., Chen, J., Yang, J., Yan, J., Xia, Y., Zhang, F., Wang, X., & Cao, H. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108998 · Cited by 99
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
Horne, A. M., Mihov, B., & Reid, I. R. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0404-6 · Cited by 95
Current concepts in osteogenesis imperfecta: Bone structure, biomechanics and medical management
Nijhuis, W. H., Eastwood, D. M., Allgrove, J., Hvid, I., Weinans, H., Bank, R. A., & Sakkers, R. J. B. (2019) · Journal of Children s Orthopaedics · doi:10.1302/1863-2548.13.180190 · Cited by 123
Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Bastin, S., & Gamble, G. D. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3860 · Cited by 93
Langdahl, B. L. (2020) · Bone · doi:10.1016/j.bone.2020.115516 · Cited by 95
Glucocorticoid-Induced Osteoporosis: Why Kids Are Different
Ward, L. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00576 · Cited by 96
MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis
CANALIS, E. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0920 · Cited by 94
Osteoanabolic and dual action drugs
Tabacco, G., & Bilezikian, J. P. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13766 · Cited by 92
Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes
Gado, M., Baschant, U., Hofbauer, L. C., & Henneicke, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.835720 · Cited by 95
Self-citationWang, L., Yu, Y., Ni, S., Li, D., Liu, J., Xie, D., Chu, H. Y., Ren, Q., Zhong, C., Zhang, N., et al. (2022) · Theranostics · doi:10.7150/thno.63177 · Cited by 93
Self-citationYe, C., Ebeling, P. R., & Kline, G. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01385-6 · Cited by 99
Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition
Witcher, P. C., Miner, S. E., Horan, D. J., Bullock, W. A., Lim, K., Kang, K. S., Adaniya, A. L., Ross, R. D., Loots, G. G., & Robling, A. G. (2018) · JCI Insight · doi:10.1172/jci.insight.98673 · Cited by 93
Singh, S., Dutta, S., Khasbage, S. U., Kumar, T., Sachin, J., Sharma, J., & Varthya, S. B. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06095-y · Cited by 96
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
Leder, B. Z. (2018) · JBMR Plus · doi:10.1002/jbm4.10041 · Cited by 90
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
Schemitsch, E. H., Miclau, T., Karachalios, T. S., Nowak, L. L., Sancheti, P. K., Poolman, R. W., Caminis, J. N., Daizadeh, N. S., Dent-Acosta, R. E., Egbuna, O. I., et al. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.19.00790 · Cited by 89
Self-citationThe Endosteal Niche in Breast Cancer Bone Metastasis
Haider, M., Smit, D. J., & Taipaleenmäki, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00335 · Cited by 87
Kvist, A. V., Faruque, J., Vallejo‐Yagüe, E., Weiler, S., Winter, E. M., & Burden, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081660 · Cited by 93
Recent Progresses in the Treatment of Osteoporosis
Li, S., He, S., Xie, P.-Y., Li, W., Zhang, X., Li, T.-F., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717065 · Cited by 91
Osteoporosis, bone mineral density and CKD–MBD: treatment considerations
Bover, J., Bailone, L., López‐Báez, V., Benito, S., Ciceri, P., Galassi, A., & Cozzolino, M. G. (2017) · Journal of Nephrology · doi:10.1007/s40620-017-0404-z · Cited by 87
Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis
Ramchand, S. K., & Leder, B. Z. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad496 · Cited by 86
A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction
Sato, T., Verma, S., Andrade, C. D. C., Omeara, M., Campbell, N., Wang, J. S., Cetinbas, M., Lang, A., Ausk, B. J., Brooks, D. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17099-3 · Cited by 86
Somatic activating mutations in MAP2K1 cause melorheostosis
Kang, H., Jha, S., Deng, Z., Fratzl‐Zelman, N., Cabral, W. A., Ivovic, A., Meylan, F., Hanson, E. P., Lange, E., Katz, J. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03720-z · Cited by 87
Understanding and managing corticosteroid-induced osteoporosis
Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s282606 · Cited by 84
Self-citationRole of Osteocyte-PDL Crosstalk in Tooth Movement via SOST/Sclerostin
Odagaki, N., Ishihara, Y., Wang, Z., Hlaing, E. E., Nakamura, M., Hoshijima, M., Hayano, S., Kawanabe, N., & Kamioka, H. (2018) · Journal of Dental Research · doi:10.1177/0022034518771331 · Cited by 85
Romosozumab: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01072-6 · Cited by 84
Cosman, F., Crittenden, D. B., Ferrari, S., Lewiecki, E. M., Jaller-Raad, J. J., Zerbini, C. A. F., Milmont, C. E., Meisner, P. D., Libanati, C. R., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3439 · Cited by 82
Self-citationA Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.004 · Cited by 81
Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone
Shibahara, T. (2019) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.247.75 · Cited by 82
Bone health in diabetes and prediabetes
Costantini, S., & Conte, C. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.421 · Cited by 84
From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights
Anesi, A., Generali, L., Sandoni, L., Pozzi, S., & Grande, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194925 · Cited by 83
Skeletal responses to romosozumab after 12 months of denosumab
McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J., Langdahl, B. L., Shi, Y., Timoshanko, J., Libanati, C. R., Chines, A. A., & Oates, M. K. (2021) · JBMR Plus · doi:10.1002/jbm4.10512 · Cited by 83
Self-citationOsteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment
Sabri, S. A., Chavarria, J. C., Ackert‐Bicknell, C. L., Swanson, C. M., & Burger, E. L. (2022) · Orthopedics · doi:10.3928/01477447-20220719-03 · Cited by 84
Effect of Bifidobacterium on osteoclasts: TNF-α/NF-κB inflammatory signal pathway-mediated mechanism
Wu, Y., Yang, Y., Wang, L., Chen, Y., Han, X., Sun, L., Chen, H., & Chen, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1109296 · Cited by 85
Metadata
- Authors
- Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., Zerbini, C. A. F., Milmont, C. E., Chen, L., Maddox, J., Meisner, P. D., Libanati, C., & Grauer, A.
- Affiliations
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-20
- Volume
- 375
- Issue
- 16
- Pages
- 1532-1543
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2520995084
- Cited by
- 1,805
- References
- 24
- Citations by year
- 2026: 225 · 2025: 223 · 2024: 219 · 2023: 168 · 2022: 194 · 2021: 192 · 2020: 182 · 2019: 141 · 2018: 131 · 2017: 110 · 2016: 16
- FWCI
- 161.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, osteoporosis, postmenopausal women, vertebral fractures, non-vertebral fractures, denosumab, bone formation, bone resorption, fracture risk reduction, monoclonal antibodies, adverse events, hyperostosis, cardiovascular events, osteoarthritis, cancer risk, RANKL
- MeSH terms
- Denosumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Bone Remodeling, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
